Eledon Pharmaceuticals, Inc. reported its second quarter 2025 operating and financial results on August 14, 2025. The company reported cash, cash equivalents, and short-term investments totaling $107.6 million as of June 30, 2025, and expects this to fund operations through the end of 2026.
Research and development (R&D) expenses for Q2 2025 were $20.3 million, an increase from $10.1 million in Q2 2024, reflecting continued investment in its clinical programs. General and administrative (G&A) expenses remained stable at $4.5 million compared to $4.4 million in the prior-year period.
The net loss for Q2 2025 was $11.2 million, or $0.13 per basic common share, a significant improvement from a net loss of $44.9 million, or $0.92 per basic common share, in Q2 2024. The company highlighted updated data from its Phase 1b trial, which demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant for patients on tegoprubart.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.